Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2016 Dec 2;6:38305. doi: 10.1038/srep38305

Elevated cerebral spinal fluid biomarkers in children with mucopolysaccharidosis I-H

Gerald V Raymond 1, Marzia Pasquali 2, Lynda E Polgreen 3, Patricia I Dickson 3, Weston P Miller 4, Paul J Orchard 4, Troy C Lund 4,a
PMCID: PMC5133554  PMID: 27910891

Abstract

Mucopolysaccharidosis (MPS) type-IH is a lysosomal storage disease that results from mutations in the IDUA gene causing the accumulation of glycosaminoglycans (GAGs). Historically, children with the severe phenotype, MPS-IH (Hurler syndrome) develop progressive neurodegeneration with death in the first decade due to cardio-pulmonary complications. New data suggest that inflammation may play a role in MPS pathophysiology. To date there is almost no information on the pathophysiologic changes within the cerebral spinal fluid (CSF) of these patients. We evaluated the CSF of 25 consecutive patients with MPS-IH. While CSF glucose and total protein were within the normal range, we found a significantly mean elevated CSF opening pressure at 24 cm H2O (range 14–37 cm H2O). We observed a 3-fold elevation in CSF heparan sulfate and a 3–8 fold increase in MPS-IH specific non-reducing ends, I0S0 and I0S6. Cytokine analyses in CSF of children with MPS-IH showed significantly elevated inflammatory markers including: MCP-1 SDF-1a, IL-Ra, MIP-1b, IL-8, and VEGF in comparison to unaffected children. This is the largest report of CSF characteristics in children with MPS-IH. Identification of key biomarkers may provide further insight into the inflammatory-mediated mechanisms related to MPS diseases and perhaps lead to improved targeted therapies.

Severe mucopolysaccharidosis type I, Hurler’s syndrome (MPS-IH), is a lysosomal storage disease due to mutations in the IDUA gene resulting in decreased/absent alpha-L-iduronidase activity. The consequent accumulation of the glycosaminoglycans (GAGs), heparan sulfate (HS) and dermatan sulfate (DS), in tissues results in a number of clinical features including hepatosplenomegaly, progressive cognitive impairment, cardiovascular complications, and joint and bone abnormalities (dysostosis multiplex)1. Currently, exogenous enzyme replacement using recombinant alpha-L-iduronidase is available to patients with MPS-I, although it does not cross the blood brain barrier in significant amounts2.

To achieve continuous enzyme delivery as well as provide a cerebral source of cells expressing alpha-L-iduronidase (presumed to be microglia), hematopoietic cell transplant (HCT) is used as standard of care for patients with Hurler syndrome3,4. HCT leads to an increase in IDUA enzyme activity and concomitant reductions in substrate levels as well as stabilization of neurodegeneration5,6,7. HCT does not arrest the progression of joint and bone disease8,9,10,11, nor does it reverse the characteristic changes in the heart valves12,13. These observations suggest that GAG accumulation is not the sole mediator of disease-related complications in MPS-IH14. Recent work in rodent models supports that co-existent immune and microglial inflammatory processes contribute to the pathology of several MPS diseases with demonstrating several key inflammatory cytokines including IL-6, IL-8, MIP1-beta, MIP1-alpha, and MCP-115,16,17.

As mentioned, prior to the development of HCT, children with MPS-IH were observed to develop progressive, debilitating developmental and cognitive deterioration7. While there have been several descriptions of various plasma biomarkers for MPS-IH5,18,19,20,21, no study has systematically evaluated the cerebrospinal fluid (CSF). Here, we document for the first time, the characteristics of MPS-IH CSF with a focus on inflammatory cytokines.

Results

We performed a lumbar puncture and CSF analysis on 25 consecutive patients with MPS-IH with a median age of 11.2 months. Nearly all CSF was free from erythrocytes or white blood cells. As shown in Fig. 1, the mean CSF glucose concentration was 47.6 (range 32.2–60.1 mg/dL), with the normal range for age being 40–70 mg/dL. The mean CSF total protein was 30.8 (range 9.3–61.6 mg/dL), with a normal range for age of 15–60 mg/dL. Strikingly, we found a significant elevation in opening pressure (OP) in children with MPS-IH, with a mean of 24.6 cm H2O (range 14–37 cm H2O). This is higher than what is considered a normal OP in children of this age, which is <20 cm H2O22.

Figure 1. CSF opening pressure (OP), glucose, and total protein in MPS-IH patients.

Figure 1

Open in a new tab

The boxes represent to 25th to 75th percentiles with a line at the mean. Whiskers show the 10th and 90th percentiles. Symbols represent value outside the 10 – 90th percentile. The yellow area indicates the normal range for age at our institution.

Using the Sensi-Pro ® assay, we measured NREs characteristic for MPS-IH, I0S0 and I0S6, and also determined total HS concentration19. We found a significant elevation in I0S0 and I0S6 with an average of 56.3 and 249.1 ng/mL respectively (with normal values of <15 and <30 ng/mL, respectively19) as shown in Fig. 2. Total HS was also significantly elevated with an average of 278.1 ± 108.2 ng/mL (normal <120 ng/mL) (Fig. 2).

Figure 2. Non-reducing ends (NRE)s, I0S0 and I0S6, and total HS content in MPS-IH CSF.

Figure 2

Open in a new tab

The boxes represent to 25th to 75th percentiles with a line at the mean. Whiskers show the 10th and 90th percentiles. Symbols represent value outside the 10 – 90th percentile. The yellow area indicates the normal range in the general population.

We also evaluated HCII-T (heparin cofactor II-thrombin) complex, a previously described biomarker of lysosomal storage diseases including MPS-IH18. We found a significant elevation with a mean level of 4.5 ± 1.4 ng/mL of HCII-T complex (reference range: <0.25 ng/mL) (Fig. 3).

Figure 3. Levels of HCII-T in MPS-IH CSF.

Figure 3

Open in a new tab

The boxes represent to 25th to 75th percentiles with a line at the mean. Whiskers show the 10th and 90th percentiles. Symbols represent value outside the 10 – 90th percentile. The yellow area indicates the non-MPS reference. N = 10 MPS-IH patients. The reference value was determined from the average of four non-MPS samples.

We found six inflammatory markers to be significantly elevated in children with MPS-IH when compared to controls: monocyte chemoattractant protein-1 (MCP-1) (mean 811 vs 328 pg/mL, p < 0.001), stromal cell-derived factor-1a (SDF-1a) (784 vs 200 pg/mL, p < 0.0001), interleukin-1 receptor antagonist (IL-Ra) (62 vs 6 pg/mL, p < 0.0001), macrophage inflammatory protein 1-beta (MIP-1b) (13.1 vs 3.3 pg/mL, p = 0.04), interleukin-8 (IL-8) (39 vs 17 pg/mL, p < 0.0001), and vascular endothelial growth factor (VEGF) (5.1 vs 0.1 pg/mL, p < 0.0001) as shown Fig. 4.

Figure 4. CSF Inflammatory cytokines in MPS-IH patients.

Figure 4

Open in a new tab

Shown are the factors that demonstrated significant elevation in the MPS-IH group. Error bars represent standard error of the mean and p-values were generated from a Student’s t-test. *p < 0.05, ***p < 0.001.

Discussion

We report potential CSF biomarkers for patients with MPS-IH. These may be important to consider as further therapies are being developed either through immunomodulation, hematopoietic stem cell transplant, new forms of enzyme therapy and other interventions. These biomarkers may serve as indicators to which we can compare the effectiveness of new interventions. In addition, they may prove useful as a means of identifying future phenotypes in children diagnosed through newborn screening that display novel or poorly characterized genotypes.

We found the mean CSF OP was higher in children with MPS-IH than what is considered “typical” for healthy children, which is <20 cm H2022. Recently, Avery et al. analyzed the OP of 197 children and found a mean OP of 19.6 cm H2023. Furthermore, given the 10th/90th percentage of Avery’s data was 11.5 and 28 cm H2O, it has been suggested that an abnormal OP should be consider that of >28 cm H2O23,24. Six of 25 MPS-IH patients had OP greater than 30 cm H2O. While sedation and changes in ventilation can both modulate the OP24, our patients all had strict end-tidal CO2 monitored and maintained from 25–40 mm Hg. Classically, elevated OP is associated with intracranial processes such as infection (bacterial, viral, or fungal meningitis), subarachnoid hemorrhage, pseudotumor cerebri, or any communicating hydrocephalus. Our data suggest that GAG accumulation and perhaps subacute neuroinflammation may contribute to an increase in OP. We should note that none of our patients has evidence of papilledema suggesting that their increased OP was not severe enough to affect the optic nerve head.

An inflammatory process has been implicated as a pathological contributor to MPS disease21, with specific contributions to skeletal manifestations. Simonaro et al. previously found TNF-alpha to be elevated in MPS VII mice and treatment of MPS VI affected rats with Infliximab, an antibody targeted to TNF-alpha, significantly reduced joint disease15. Additionally, the anti-inflammatory compound, pentosan polysulfate, has been shown to reduce inflammation associated bone pathology in a rat model of MPS VII and is now entering clinical trials in MPS patients25.

In this study, we demonstrate for the first time that markers of inflammation are manifest in the CSF of MPS patients. Our data is consistent with what others have shown in the brain of MPS animal models. For example, Wilkinson et al. showed significantly high levels of MCP-1 in the brain of MPSI, MPSIIIA, and MPSIIIB mice17. The links between the immune system of MPS pathology as it relates to the neurological and skeletal system is becoming more appreciated26. It is doubtful that a single cytokine or inflammatory factor is responsible for MPS pathology, as many of the inflammatory proteins exist in a “cascade” of factors where initiation of inflammation is followed by waves of chemokine secretion and recruitment of immune cells. Several of the elevated factors we show here are also associated with other neuroinflammatory conditions, including MCP-1 and MIP-1b which are elevated in patients with multiple sclerosis, while MCP-1, MIP-1b, IL-8, and SDF-1a are elevated in stroke victims27.

Whether the CSF inflammatory mediators are due to GAG accumulation or another process is not known. There are very few reports of CSF GAG evaluation in patients afflicted with a mucopolysaccharidosis diagnosis28,29,30, and we believe this is the first study to evaluate non-reduced ends (NREs) and HS levels in the CSF of MPS-IH patients. Clinical trials investigating the use of anti-inflammatory agents are being developed in MPS-I and other MPS subtypes for the purpose of ameliorating joint and bone disease25. Novel attempts at targeting the CSF with recombinant viral vectors delivering the missing enzyme are being developed in several MPS diseases as well31,32,33,34,35. Commonly, glycan-based markers are used to show efficacy for these various strategies36. Based on our CSF findings, it may also be important to collect and assess both CSF GAG and inflammatory markers as new clinical trials evolve, since reducing inflammation will likely coincide with an impact on neurological processes and perhaps skeletal disease as noted above.

Methods

Participants

Patients with MPS-IH (n = 25, median age of 11.2 months, range 6–30 months) had CSF sampling performed 8 weeks prior to hematopoietic stem cell transplant at the University of Minnesota. During the initial evaluation including a sedated MRI, a lateral decubitus lumbar puncture is routinely performed with an opening pressure (OP) measurement and CSF was obtained and analyzed for cell count, protein concentration, glucose concentration, GAG concentration and cytokine analysis. End-tidal CO2 monitored and maintained from 25–40 mm Hg to ensure opening pressure accuracy.

Control patients for biomarker analyses (n = 25, median age 6.8 years, range 4–17 years) were those undergoing intrathecal chemotherapy for a prior diagnosis of acute lymphoblastic leukemia, at least 3 months into maintenance therapy, and without a CSF leukemia diagnosis. In controls, CSF was withdrawn just prior to administration of the intrathecal chemotherapy and cytokine concentrations determined by ELISA. Unavailability of “healthy” controls due to the risks inherent to attaining CSF from “healthy” children established these patients as the most appropriate control group available and has been previously published by our group and others37,38,39. This study was approved by the Committee on the Use of Human Subjects in Research at the University of Minnesota, and all experiments were performed in accordance with relevant guidelines and regulations by the Committees on the Use of Human Subjects in Research at the University of Minnesota. Informed written consent was obtained for all patient samples from the parents or guardians on behalf of the child participants.

Cytokines

CSF samples were evaluated using the 22-plex, human panel A, (R&D Systems, Minneapolis, MN) measured with the Luminex system (Luminex, Austin, TX) and analyzed by Bioplex software (BioRad, Hercules, CA). This panel includes ENA-78, bFGF, G-CSF, GM-CSF, IFN-gamma, IL-1alpha, IL-1beta, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-17, MCP-1, MIP-1alpha, MIP-1beta, RANTES, TNF-alpha, TPO, and VEGF as shown in Table 1. SDF-1alpha was measured by sandwich ELISA (R&D Systems, Minneapolis, MN).

Table 1. List of inflammatory factors evaluated in CSF samples.

Cytokine Name Abbreviation
Epithelial derived neutrophil activating peptide 78 or CXCL5 ENA-78
Basic fibroblast growth factor bFGF
Granulocyte colony stimulating factor G-CSF
Granulocyte macrophage colony stimulating factor GM-CSF
Interferon gamma IFN-gamma
Interleukin 1alpha IL-1alpha
Interleukin 2beta IL-1beta
Interleukin 1 receptor antagonist IL-1ra
Interleukin 2 IL-2
Interleukin 4 IL-4
Interleukin 5 IL-5
Interleukin 6 IL-6
Interleukin 8 IL-8
Interleukin 10 IL-10
Interleukin 17 IL-17
Monocyte chemotactic protein 1 or CCL2 MCP-1
Macrophage inflammatory protein 1alpha or CCL3 MIP-1a
Macrophage inflammatory protein 1beta or CCL4 MIP-1b
Regulated upon activation, Normal T-cell expressed or CCL5 RANTES
Tumor necrosis factor alpha TNF-alpha
Thrombopoietin TPO
Vascular endothelial growth factor VEGF
Stromal derived factor 1alpha SDF-1alpha
Open in a new tab

Heparin cofactor II-thrombin (HCII-T)

HCII-T complex was determined by ELISA, following the manufacturer’s instruction (#MBS904277, Mybiosource, San Diego, CA).

Non-Reducing Ends (NREs) and total HS

The CSF NREs (I0S0 and I0S6) and total HS (calculated from the addition of the internal disaccharides, D0A0 + D0S0) were determined using the Sensi-Pro ® assay as previously described19.

Statistical methods

Cytokine measurements were made in duplicate and the average of the two values was used to determine concentration using standard curves generated with the relevant recombinant human proteins provided with the commercial kits. Means for the MPS-IH and control groups were calculated and subjected to a two-tailed Student’s t-test to compute a p-value.

Additional Information

How to cite this article: Raymond, G. V. et al. Elevated cerebral spinal fluid biomarkers in children with mucopolysaccharidosis I-H. Sci. Rep. 6, 38305; doi: 10.1038/srep38305 (2016).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgments

Research was supported in part by the Children’s Cancer Research Fund. We acknowledge the University of Minnesota Cytokine Reference Laboratory for their assistance.

Footnotes

Author Contributions T.C.L. and P.J.O. provided the study concept and design. All authors contributed to the acquisition, analysis, or interpretation of data. T.C.L. drafted the manuscript. M.P. measured the NREs and provided critical analysis. W.P.M., M.P., G.V.R., L.E.P., P.I.D. provided critical revision of the manuscript for important intellectual content. T.C.L. provided statistical analysis.

References

  1. Muenzer J., Wraith J. E. & Clarke L. A., Management, a. t. I. C. P. o. t. & I, T. o. M. Mucopolysaccharidosis I: Management and Treatment Guidelines. Pediatrics 123, 19–29, doi: 10.1542/peds.2008-0416 (2009). [DOI] [PubMed] [Google Scholar]
  2. Shull R. M. et al. Enzyme replacement in a canine model of Hurler syndrome. Proceedings of the National Academy of Sciences of the United States of America 91, 12937–12941 (1994). [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Valayannopoulos V. & Wijburg F. A. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford) 50 Suppl 5, v49-59, doi: 10.1093/rheumatology/ker396 (2011). [DOI] [PubMed] [Google Scholar]
  4. Prasad V. K. & Kurtzberg, J. Transplant outcomes in mucopolysaccharidoses. Seminars in hematology 47, 59–69, doi: 10.1053/j.seminhematol.2009.10.008 (2010). [DOI] [PubMed] [Google Scholar]
  5. Church H. et al. Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone marrow transplantation 39, 207–210, doi: 10.1038/sj.bmt.1705569 (2007). [DOI] [PubMed] [Google Scholar]
  6. Kunin-Batson A. S. et al. Long-Term Cognitive and Functional Outcomes in Children with Mucopolysaccharidosis (MPS)-IH (Hurler Syndrome) Treated with Hematopoietic Cell Transplantation. JIMD reports, doi: 10.1007/8904_2015_521 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hobbs J. R. et al. Reversal of clinical features of Hurler’s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 2, 709–712 (1981). [DOI] [PubMed] [Google Scholar]
  8. Weisstein J. S., Delgado E., Steinbach L. S., Hart K. & Packman S. Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop 24, 97–101 (2004). [DOI] [PubMed] [Google Scholar]
  9. Polgreen L. E. et al. Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation. Bone marrow transplantation 41, 1005–1011, doi: 10.1038/bmt.2008.20 (2008). [DOI] [PubMed] [Google Scholar]
  10. Gardner C. J. et al. Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H). Journal of inherited metabolic disease 34, 489–497, doi: 10.1007/s10545-010-9262-8 (2011). [DOI] [PubMed] [Google Scholar]
  11. Oussoren E., Brands M. M., Ruijter G. J., der Ploeg A. T. & Reuser A. J. Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options. Biochimica et biophysica acta 1812, 1542–1556, doi: 10.1016/j.bbadis.2011.07.013 (2011). [DOI] [PubMed] [Google Scholar]
  12. Wang R. Y. et al. Carotid intima-media thickness is increased in patients with treated mucopolysaccharidosis types I and II, and correlates with arterial stiffness. Molecular genetics and metabolism 111, 128–132, doi: 10.1016/j.ymgme.2013.11.001 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Schroeder L. et al. Cardiac Ultrasound Findings in Infants with Severe (Hurler Phenotype) Untreated Mucopolysaccharidosis (MPS) Type I. JIMD reports 10, 87–94, doi: 10.1007/8904_2012_208 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Stoop F. J. et al. Prevalence and development of orthopaedic symptoms in the dutch hurler patient population after haematopoietic stem cell transplantation. JIMD reports 9, 17–29, doi: 10.1007/8904_2012_175 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Simonaro C. M. et al. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proceedings of the National Academy of Sciences of the United States of America 107, 222–227, doi: 10.1073/pnas.0912937107 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Archer L. D., Langford-Smith K. J., Bigger B. W. & Fildes J. E. Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity. Journal of inherited metabolic disease 37, 1–12, doi: 10.1007/s10545-013-9613-3 (2014). [DOI] [PubMed] [Google Scholar]
  17. Wilkinson F. L. et al. Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB. PloS one 7, e35787, doi: 10.1371/journal.pone.0035787 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Randall D. R., Sinclair G. B., Colobong K. E., Hetty E. & Clarke L. A. Heparin cofactor II-thrombin complex in MPS I: a biomarker of MPS disease. Molecular genetics and metabolism 88, 235–243, doi: 10.1016/j.ymgme.2006.01.005 (2006). [DOI] [PubMed] [Google Scholar]
  19. Lawrence R. et al. Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nat Chem Biol 8, 197–204, doi: 10.1038/nchembio.766 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Stevenson D. A. et al. Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI. J Pediatr Rehabil Med 7, 159–165, doi: 10.3233/PRM-140285 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Polgreen L. E. et al. Elevated TNF-alpha is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI. Molecular genetics and metabolism 117, 427–430, doi: 10.1016/j.ymgme.2016.01.012 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Custer J. W., Rau R. E. & Johns Hopkins Hospital. Children’s Medical and Surgical Center. The Harriet Lane handbook : a manual for pediatric house officers. 18th edn, (Mosby/Elsevier, 2009). [Google Scholar]
  23. Avery R. A. Reference range of cerebrospinal fluid opening pressure in children: historical overview and current data. Neuropediatrics 45, 206–211, doi: 10.1055/s-0034-1376202 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Avery R. A. et al. Reference range for cerebrospinal fluid opening pressure in children. The New England journal of medicine 363, 891–893, doi: 10.1056/NEJMc1004957 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Schuchman E. H. et al. Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PloS one 8, e54459, doi: 10.1371/journal.pone.0054459 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Opoka-Winiarska V., Jurecka A., Emeryk A. & Tylki-Szymanska A. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 21, 1813–1823, doi: 10.1016/j.joca.2013.08.001 (2013). [DOI] [PubMed] [Google Scholar]
  27. Bajetto A., Bonavia R., Barbero S. & Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. Journal of Neurochemistry 82, 1311–1329, doi: 10.1046/j.1471-4159.2002.01091.x (2002). [DOI] [PubMed] [Google Scholar]
  28. Naimy H. et al. A novel LC-MS/MS assay for heparan sulfate screening in the cerebrospinal fluid of mucopolysaccharidosis IIIA patients. Bioanalysis 8, 285–295, doi: 10.4155/bio.15.243 (2016). [DOI] [PubMed] [Google Scholar]
  29. Jones S. A. et al. A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Molecular genetics and metabolism, doi: 10.1016/j.ymgme.2016.05.006 (2016). [DOI] [PubMed] [Google Scholar]
  30. Zhang H. et al. Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry. Clin Chem 57, 1005–1012, doi: 10.1373/clinchem.2010.161141 (2011). [DOI] [PubMed] [Google Scholar]
  31. Marshall N. R. et al. Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods. Experimental neurology 263, 79–90, doi: 10.1016/j.expneurol.2014.09.008 (2015). [DOI] [PubMed] [Google Scholar]
  32. Beard H. et al. Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice. Molecular genetics and metabolism 115, 33–40, doi: 10.1016/j.ymgme.2015.03.002 (2015). [DOI] [PubMed] [Google Scholar]
  33. Murrey D. A. et al. Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates. Human gene therapy. Clinical development 25, 72–84, doi: 10.1089/humc.2013.208 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Kan S. H. et al. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB. Proceedings of the National Academy of Sciences of the United States of America 111, 14870–14875, doi: 10.1073/pnas.1416660111 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Hemsley K. M. & Hopwood J. J. Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases. International journal of clinical pharmacology and therapeutics 47 Suppl 1, S118–123 (2009). [DOI] [PubMed] [Google Scholar]
  36. Lawrence R. et al. Glycan-based biomarkers for mucopolysaccharidoses. Molecular genetics and metabolism 111, 73–83, doi: 10.1016/j.ymgme.2013.07.016 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Orchard P. J. et al. Chitotriosidase as a biomarker of cerebral adrenoleukodystrophy. Journal of neuroinflammation 8, 144, doi: 10.1186/1742-2094-8-144 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Thibert K. A. et al. Cerebrospinal fluid matrix metalloproteinases are elevated in cerebral adrenoleukodystrophy and correlate with MRI severity and neurologic dysfunction. PLoS One 7, e50430, doi: 10.1371/journal.pone.0050430 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Lund T. C. et al. Elevated cerebral spinal fluid cytokine levels in boys with cerebral adrenoleukodystrophy correlates with MRI severity. PLoS One 7, e32218, doi: 10.1371/journal.pone.0032218 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES